Cover Image
市場調查報告書

轉移性肝癌 (HCC):開發中產品分析

Metastatic Hepatocellular Carcinoma (HCC) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 213063
出版日期 內容資訊 英文 131 Pages
訂單完成後即時交付
價格
Back to Top
轉移性肝癌 (HCC):開發中產品分析 Metastatic Hepatocellular Carcinoma (HCC) - Pipeline Review, H2 2016
出版日期: 2016年08月31日 內容資訊: 英文 131 Pages
簡介

所謂轉移性肝癌 (HCC) 是指在肝臟發病,並轉移到肺、淋巴結、腎上腺、骨(包含頭蓋骨)等部位的癌症。主要症狀有腹痛和壓痛 (特別是腹右上部),挫傷·出血症,腹部膨脹,黃疸 (眼睛和皮膚變黃) 等。主要的易罹病素質包含飲酒過度,及肝臟的自體免疫疾病,B型·C型肝炎病毒的感染,血鐵沉著症等。主要的治療方法有外科手術和化療,放射治療等。

本報告提供全球各國治療轉移性肝癌 (HCC) 所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

轉移性肝癌 (HCC)的概要

治療藥的開發

  • 轉移性肝癌開發中產品:概要
  • 轉移性肝癌開發中產品:比較分析

各企業開發中的的HCC治療藥

大學/研究機關研究中的HCC治療藥

開發中產品的概要

  • 臨床實驗階段的產品
  • 初期階段的產品

轉移性肝癌治療藥:開發中的產品一覽 (各企業)

轉移性肝癌治療藥:研究中的產品一覽 (各大學/研究機關)

轉移性肝癌開發治療藥的企業

  • Acceleron Pharma, Inc.
  • AstraZeneca Plc
  • AVEO Pharmaceuticals, Inc.
  • Celgene Corporation
  • Eisai
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • HanAll Biopharma Co., Ltd.
  • Johnson & Johnson
  • Millennium Pharmaceuticals Inc
  • Mirna Therapeutics, Inc.
  • Molecular Partners AG
  • MolMed S.p.A.
  • Novartis AG
  • OncoMed Pharmaceuticals, Inc.
  • Pfizer Inc.
  • PharmAbcine, Inc.
  • Verlyx Pharma Inc.

轉移性肝癌 (HCC):治療藥的評估

  • 單劑治療藥的情況
  • 標的別
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

轉移性肝癌治療藥:開發暫停的產品

轉移性肝癌治療藥:開發中止的產品

轉移性肝癌相關產品的開發里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8419IDB

Summary

Global Markets Direct's, 'Metastatic Hepatocellular Carcinoma (HCC) - Pipeline Review, H2 2016', provides an overview of the Metastatic Hepatocellular Carcinoma (HCC) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Metastatic Hepatocellular Carcinoma (HCC), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Metastatic Hepatocellular Carcinoma (HCC) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Metastatic Hepatocellular Carcinoma (HCC)
  • The report reviews pipeline therapeutics for Metastatic Hepatocellular Carcinoma (HCC) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Metastatic Hepatocellular Carcinoma (HCC) therapeutics and enlists all their major and minor projects
  • The report assesses Metastatic Hepatocellular Carcinoma (HCC) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Metastatic Hepatocellular Carcinoma (HCC)

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Metastatic Hepatocellular Carcinoma (HCC)
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Metastatic Hepatocellular Carcinoma (HCC) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Metastatic Hepatocellular Carcinoma (HCC) Overview
  • Therapeutics Development
    • Pipeline Products for Metastatic Hepatocellular Carcinoma (HCC) - Overview
    • Pipeline Products for Metastatic Hepatocellular Carcinoma (HCC) - Comparative Analysis
  • Metastatic Hepatocellular Carcinoma (HCC) - Therapeutics under Development by Companies
  • Metastatic Hepatocellular Carcinoma (HCC) - Therapeutics under Investigation by Universities/Institutes
  • Metastatic Hepatocellular Carcinoma (HCC) - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Metastatic Hepatocellular Carcinoma (HCC) - Products under Development by Companies
  • Metastatic Hepatocellular Carcinoma (HCC) - Products under Investigation by Universities/Institutes
  • Metastatic Hepatocellular Carcinoma (HCC) - Companies Involved in Therapeutics Development
    • Acceleron Pharma, Inc.
    • AstraZeneca Plc
    • AVEO Pharmaceuticals, Inc.
    • Celgene Corporation
    • Eisai Co., Ltd.
    • Eli Lilly and Company
    • F. Hoffmann-La Roche Ltd.
    • HanAll Biopharma Co., Ltd.
    • Johnson & Johnson
    • Millennium Pharmaceuticals Inc
    • Mirna Therapeutics, Inc.
    • Molecular Partners AG
    • MolMed S.p.A.
    • Novartis AG
    • OncoMed Pharmaceuticals, Inc.
    • Pfizer Inc.
    • PharmAbcine, Inc.
    • Verlyx Pharma Inc.
  • Metastatic Hepatocellular Carcinoma (HCC) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AV-203 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AZD-9150 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CC-122 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cellular Immunotherapy for Metastatic Hepatocellular Carcinoma - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • codrituzumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • crizotinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dalantercept - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • emibetuzumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • erdafitinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • golvatinib tartrate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HL-143 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ipafricept - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LY-3039478 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LY-3127804 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MP-0250 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MRX-34 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NGR-hTNF - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OSU-2S - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • palbociclib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pasireotide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pentamidine isethionate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PF-04518600 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PTX-9908 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • sapanisertib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • sonidegib phosphate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • temsirolimus - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TTAC-0001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • utomilumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Metastatic Hepatocellular Carcinoma (HCC) - Dormant Projects
  • Metastatic Hepatocellular Carcinoma (HCC) - Discontinued Products
  • Metastatic Hepatocellular Carcinoma (HCC) - Product Development Milestones
    • Featured News & Press Releases
      • Jul 30, 2013: Mirna Therapeutics Announces Important Expansion of microRNA Patent Portfolio
      • May 13, 2013: Marina Biotech's Licensee Mirna Therapeutics Initiates Phase I Clinical Trial Of Anticancer Drug MRX34
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Metastatic Hepatocellular Carcinoma (HCC), H2 2016
  • Number of Products under Development for Metastatic Hepatocellular Carcinoma (HCC) - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by Acceleron Pharma, Inc., H2 2016
  • Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by AstraZeneca Plc, H2 2016
  • Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by AVEO Pharmaceuticals, Inc., H2 2016
  • Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by Celgene Corporation, H2 2016
  • Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by Eisai Co., Ltd., H2 2016
  • Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by Eli Lilly and Company, H2 2016
  • Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
  • Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by HanAll Biopharma Co., Ltd., H2 2016
  • Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by Johnson & Johnson, H2 2016
  • Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by Millennium Pharmaceuticals Inc, H2 2016
  • Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by Mirna Therapeutics, Inc., H2 2016
  • Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by Molecular Partners AG, H2 2016
  • Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by MolMed S.p.A., H2 2016
  • Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by Novartis AG, H2 2016
  • Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by OncoMed Pharmaceuticals, Inc., H2 2016
  • Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by Pfizer Inc., H2 2016
  • Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by PharmAbcine, Inc., H2 2016
  • Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by Verlyx Pharma Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Metastatic Hepatocellular Carcinoma (HCC) - Dormant Projects, H2 2016
  • Metastatic Hepatocellular Carcinoma (HCC) - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Metastatic Hepatocellular Carcinoma (HCC), H2 2016
  • Number of Products under Development for Metastatic Hepatocellular Carcinoma (HCC) - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top